Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Health Catalyst (HCAT) Share-based Compensation (2018 - 2025)

Health Catalyst's Share-based Compensation history spans 8 years, with the latest figure at $4.1 million for Q4 2025.

  • For Q4 2025, Share-based Compensation fell 62.01% year-over-year to $4.1 million; the TTM value through Dec 2025 reached $27.0 million, down 32.69%, while the annual FY2025 figure was $27.0 million, 32.69% down from the prior year.
  • Share-based Compensation reached $4.1 million in Q4 2025 per HCAT's latest filing, down from $7.0 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $18.7 million in Q4 2022 to a low of $4.1 million in Q4 2025.
  • Average Share-based Compensation over 5 years is $13.0 million, with a median of $13.7 million recorded in 2021.
  • Peak YoY movement for Share-based Compensation: surged 95.97% in 2021, then plummeted 62.01% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $16.4 million in 2021, then increased by 14.17% to $18.7 million in 2022, then tumbled by 30.6% to $13.0 million in 2023, then fell by 16.9% to $10.8 million in 2024, then tumbled by 62.01% to $4.1 million in 2025.
  • Per Business Quant, the three most recent readings for HCAT's Share-based Compensation are $4.1 million (Q4 2025), $7.0 million (Q3 2025), and $8.3 million (Q2 2025).